Ege University Hospital

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Myeloproliferative neoplasms3 trials
• Diffuse large B-cell lymphoma1 trial
• Haemophilia1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Parkinson disease1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Terminated3 trials
• Active, not recruiting2 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Incyte Corporation4 trials
• Antalya Training and Research Hospital1 trial
• ApcinteX Ltd1 trial
• Ege University1 trial
• Stichting Hemato-Oncologie voor Volwassenen Nederland1 trial

Running trials

• Recruiting

  TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

  NCT07279402· Antalya Training and Research Hospital· Source

  Contact: Hasan Çağrı Yıldırım, MD

• Active, not recruiting

  Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

  NCT05429268· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

  NCT04509700· Phase 2· Incyte Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Closed trials

• Completed

  rTMS Treatment of Dysphagia in Parkinson's Patients

  NCT07221110· Ege University· Source

• Terminated

  Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

  NCT05605678· ApcinteX Ltd· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

  NCT01208766· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source